Guest Editors
Prof. Agnieszka Bojarska-Junak
Email: agnieszka.bojarska-junak@umlub.edu.pl
Affiliation: Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland
Homepage:
Research Interests: cancer immunology, macrophages, myeloid-derived suppressor cells, γδ T cells, flow cytometry
Dr. Agata Szymańska
Email: agata.szymanska@umlub.edu.pl
Affiliation: Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland
Homepage:
Research Interests: flow cytometry, cancer immunology, tumor microenvironment, immune checkpoints, leukemia
Summary
Leukemias are heterogeneous hematologic malignancies in which clinical progression and relapse are driven by evolving leukemic clones and therapy-shaped interactions with the tumor microenvironment. This Special Issue focuses on translational research that links molecular heterogeneity and immune suppression to leukemic progression, treatment resistance, and clinically actionable cancer biomarkers. We welcome original studies and focused reviews across all major leukemia types, including AML, ALL, CLL, CML, and related entities, integrating molecular profiling with immune phenotyping and longitudinal clinical follow-up. Topics of interest include cancer pathogenesis driven by recurrent genetic and epigenetic alterations; clonal selection under targeted therapy; microenvironmental niches that sustain persistence; and immune escape programs such as impaired antigen presentation, altered interferon signaling, regulatory lymphocytes, myeloid-derived suppressor networks, and checkpoint/exhaustion pathways. Submissions are particularly encouraged when they validate biomarker signatures (including MRD-linked readouts) against robust endpoints (time-to-treatment, relapse, transformation, survival), integrate multi-modal data into predictive models, and/or propose implementable assays for clinical laboratories (flow cytometry panels, targeted sequencing, or composite biomarker algorithms). By connecting mechanism to precision monitoring and therapeutic optimization, this Special Issue aims to accelerate translation of immuno-molecular insights into improved stratification and outcomes. We also encourage studies addressing immunotherapy response predictors, post-treatment immune reconstitution, and harmonized clinical assay workflows.
Keywords
molecular heterogeneity, leukemic progession, tumor microenvironment, cancer biomarkers, immune suppression, targeted therapy, cancer pathogenesis
Login
Register
Submit a Paper
Propose a Special lssue